The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak

By A. Tager, P. LaCamera, B. Shea, Gabriele S. V. Campanella, M. Selman, Zhenwen Zhao, V. Polosukhin, J. Wain, Banu A. Karimi-Shah, Nancy D. Kim and 6 more. Nature Medicine, 2008

786 citations recorded by the source corpus.

Subfields: Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/f86a69a669e16d9d1b5e2c590798c6551fc15e49

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. D. Sheppard
2. S. Friedman
3. J. Chun
4. T. Ramalingam
5. Y. Yung
6. Jeremy S. Duffield
7. TA Wynn
8. Nicole C. Stoddard

In Pulmonary and Respiratory Medicine

1. Jeremy S. Duffield
2. S. Friedman
3. TA Wynn
4. D. Sheppard
5. T. Ramalingam
6. S. Violette
7. M. C. Brotons
8. J. Yarnold

Citations in the corpus

• Integrating mechanisms of pulmonary fibrosis (2011, background): “The lysophosphatidic acid receptor 1 also controls the recruitment of fibroblasts in mice with bleomycin-induced fibrosis and levels of lysophosphatidic acid are increased in the BAL fluid of people with IPF (Tager et al., 2008).”
• Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression (2010, methodology): “C57BL/6 mice (The National Cancer Institute Animal Production Program) were instilled intratracheally with 0.05 U bleomycin (Gensia Sicor Pharmaceuticals Inc.) in 50 µl sterile saline or with 50 µl sterile saline for control mice, with lung tissue harvested 14 d later (Tager et al., 2008).”
• LPA receptor signaling: pharmacology, physiology, and pathophysiology (2014, background): “Not only does LPA mediate the progression of fibrosis via cell growth, but LPA1 has also been implicated in the initiation of disease through excessive fibroblast recruitment and persistent maintenance of leaky vasculature (251).”
• Therapy for Fibrotic Diseases: Nearing the Starting Line (2013, background): “The LPA receptor LPA1 is expressed on multiple cell types and plays a pathogenic role in tissue injury and fibrosis in mouse models (197, 198).”
• Pathogenetic mechanisms in radiation fibrosis. (2010, background): “Mice deficient for LPA receptor are protected against bleomycin-induced lung fibrosis, suggesting a connection between inflammation and fibrosis [16].”
• Mechanisms of fibrosis: therapeutic translation for fibrotic disease (2012, positive): “Antagonists of the lysophosphatidic acid-1 receptor, a growth factor that induces CTGF and TGF-β 1 expression, are being considered as treatments for kidney fibrosis, IPF and systemic sclerosis 159,160 .”